Showing results (421-430 of 654) with videos related to
Sort By:
Pageof 66
Cell|February 10, 1989
Cyclic AMP-dependent protein kinase phosphorylates and inactivates the yeast transcriptional activator ADR1J R Cherry, T R Johnson, C Dollard, et al.International Journal of Pharmaceutics|May 6, 2014
Stability study of full-length antibody (anti-TNF alpha) loaded PLGA microspheresS Marquette, C Peerboom, A Yates, et al.Reproduction (Cambridge, England)|March 16, 2004
Centromere protein b-null mice display decreasing reproductive performance through successive generations of breeding due to diminishing endometrial glandsK J Fowler, L H Wong, B K Griffiths, et al.The Prostate|March 1, 1996
Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysisB A Evans, M E Harper, C E Daniells, et al.Journal of the American Academy of Audiology|October 1, 1996
Screening for hearing loss in juvenile detention centersA E Holmes, H S Kaplan, S W Nichols, et al.Proteins|November 18, 2021
The non-prion SUP35 preexists in large chaperone-containing molecular complexesShiwha Park, Xin Wang, Wen Xi, et al.Scandinavian Journal of Urology and Nephrology. Supplementum|January 6, 2001
Prevention of prostate cancerC C Schulman, A R Zlotta, L Denis, et al.Journal of Molecular Biology|December 6, 2001
Purification and characterization of the 1.0 MDa CCR4-NOT complex identifies two novel components of the complexJ Chen, J Rappsilber, Y C Chiang, et al.Cancer Chemotherapy and Pharmacology|January 1, 1987
Current status of intravesical chemotherapy trials in the EORTC Urological Group. An overviewL Denis, C Bouffioux, K H Kurth, et al.European Urology|February 21, 1998
Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study GroupC J Tyrrell, L Denis, D Newling, et al.Pageof 66